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Abstract
Aims: Pharmacological activation of the adaptive response to hypoxia is a therapeutic strategy of growing
interest for neurological conditions, including stroke, Huntington’s disease, and Parkinson’s disease. We
screened a drug library with known safety in humans using a hippocampal neuroblast line expressing a reporter
of hypoxia-inducible factor (HIF)-dependent transcription. Results: Our screen identified more than 40 com-
pounds with the ability to induce hypoxia response element-driven luciferase activity as well or better than
deferoxamine, a canonical activator of hypoxic adaptation. Among the chemical entities identified, the anti-
helminthic benzimidazoles represented one pharmacophore that appeared multiple times in our screen. Sec-
ondary assays confirmed that antihelminthics stabilized the transcriptional activator HIF-1a and induced
expression of a known HIF target gene, p21cip1/waf1, in post-mitotic cortical neurons. The on-target effect of
these agents in stimulating hypoxic signaling was binding to free tubulin. Moreover, antihelminthic benz-
imidazoles also abrogated oxidative stress-induced death in vitro, and this on-target effect also involves binding
to free tubulin. Innovation and Conclusions: These studies demonstrate that tubulin-binding drugs can activate
a component of the hypoxic adaptive response, specifically the stabilization of HIF-1a and its downstream
targets. Tubulin-binding drugs, including antihelminthic benzimidazoles, also abrogate oxidative neuronal
death in primary neurons. Given their safety in humans and known ability to penetrate into the central nervous
system, antihelminthic benzimidazoles may be considered viable candidates for treating diseases associated
with oxidative neuronal death, including stroke. Antioxid. Redox Signal. 22, 121–134.
Introduction
Hypoxia is a fundamental, primordial stress endured bycells for billions of years. Understanding the molecular
mechanism by which metazoans adapt to hypoxia has opened
the door to new therapeutic strategies that combat hyp-
oxic insults, including those involving ischemia. Hypoxia-
inducible factor (HIF)-1 is a heterodimeric transcription
factor composed of a hypoxia-regulated HIF-1a subunit and a
constitutive HIF-1b subunit (21, 56, 59). It has been identi-
fied as one of the key molecular players of different adaptive
responses to hypoxia. This heterodimer can mediate the ex-
pression of more than 100 genes involved in cellular, local,
and systemic adaptation to a discrepancy in oxygen demand
and supply (31, 46).
Under normoxia, in each cell of the body, including neurons
and astrocytes, HIF-1a is constitutively transcribed and
translated into protein. A set of HIF prolyl hydroxylases (HIF-
PHDs) destabilizes HIF-1a in normoxia by hydroxylating it at
proline 402 and proline 564. HIF prolyl hydroxylation targets
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HIF-1a for recruitment and polyubiquitination by the Von
Hippel-Lindau (VHL) E3 Ubiquitin ligase complex, leading
to degradation by the proteasome (8, 21). Under conditions of
hypoxia, the HIF-PHDs cease to function, and HIF-1a is, thus,
not hydroxylated and degraded. The stabilized HIF-1a di-
merizes with its partner, HIF-1b, translocates to the nucleus,
and induces expression of a host of genes, including eryth-
ropoietin (EPO) and vascular endothelial growth factor
(VEGF), both of which are neuroprotective (14, 18, 38, 41).
Since the identification of this adaptive response, a number of
groups, including our own, have established that activators of
the HIF pathway are neuroprotective, especially those tar-
geting HIF-PHDs (27, 35, 37, 40, 50).
To identify novel activators of the HIF pathway in neurons
with known safety in humans, we stably transfected a hypoxia
response element (HRE) upstream of a luciferase reporter
(HRE-Luc) in immortalized hippocampal neuroblasts. We
subsequently screened these cells against a library of 1040
FDA-approved compounds, including drugs, nutriceuticals,
and reference chemicals from MicroSource Spectrum Col-
lection (Microsource Discovery, Inc.). Here, we describe the
results of our screen and the identification of antihelminthic
benzimidazoles as unexpected activators of the host adaptive
response to hypoxia in neurons in vitro and in the brain in vivo.
Since these compounds are extensively used in clinical
practice, our findings suggest they could be interesting phar-
macological candidates for the treatment of neurological
conditions involving oxidative or hypoxic stress.
Results
Identification of FDA-approved activators
of hypoxic adaptive response
To screen for activators of HIF-mediated transcription, we
used a luciferase promoter-reporter construct driven by a
68 bp region of enolase promoter containing a wild type HRE
(HRE-Luc) stably expressed in immortalized hippocampal
neuroblasts (HT22-HRE) (Fig. 1A). We have previously
shown that enolase is upregulated by hypoxia or deferox-
amine (DFO) in primary cortical neurons at both mRNA and
protein levels, and validated the reporter by showing that
DFO (10lM) induces a nearly twofold increase in luciferase
activity in HT22 cells transiently transfected with HRE-Luc.
Importantly, mutations in the HRE sequence abrogated the
response to DFO, while mutations outside the HRE did not
affect DFO-induced reporter activity (1, 61).
Innovation
By screening a hypoxia-inducible factor (HIF) reporter
expressed in a hippocampal neuroblast line against a li-
brary of clinically approved drugs, we have defined anti-
helminthic benzimidazoles as novel inducers of the
transcriptional adaptive response to hypoxia in neurons. In
contrast to cancer cells where tubulin-binding drugs in-
hibit HIF activation, we have shown that the on-target
effect of these drugs in activating hypoxic adaptation and
protecting from oxidative neuronal death is free b-tubulin.
Altogether, these results define a novel target for manip-
ulating adaptive transcriptional responses in neurons and
preventing oxidative death. Since antihelminthic benz-
imidazoles are utilized around the world for treatment
of parasitic infections, our findings suggest that they could
be employed readily in humans as hypoxia mimics and to
treat brain injury associated with oxidative stress.
FIG. 1. Large-scale screening for acti-
vators of HIF-dependent gene expression
identifies several pharmacophores, in-
cluding the antihelminthic benzimid-
azoles. (A) Schematic representation of
screening of MicroSource Spectrum collec-
tion of 1040 FDA-approved drugs and small
molecules using a luciferase reporter driven
by 68 bp of a canonical HIF-1-regulated gene
promoter (enolase) containing the HRE, sta-
bly expressed in HT22 cells. (B) Chemical
structures of benzimidazoles and DFO, a
canonical activator of hypoxic adaptive re-
sponse. The benzimidazole pharmacophore is
represented in red. The average increase of
luciferase signal for each compound is shown
in parentheses, as fold increase over control.
DFO, deferoxamine; HIF, hypoxia-inducible
factor; HRE, hypoxia response element. To
see this illustration in color, the reader is re-
ferred to the web version of this article at
www.liebertpub.com/ars
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To identify inducers of HRE-dependent transcription
with known safety in humans, we screened the 1040 com-
pound Microsource Library Collection using the HRE-
Luc-expressing HT22 cells. Each compound was added to
cells in 96-well plates at a final concentration of 10lM, in-
cluding DFO as a positive control. Luciferase activity was
normalized to cell viability in each well as measured by MTT
assay. Using this strategy, we identified a number of known
activators of the HIF pathway, including the anti-viral agent
tilorone (45), the antifungal ciclopirox (28, 53), and the anti-
hypertensive hydralazine (23), which validates our screening
tools (Table 1). Of note, the antihelminthic benzimidazoles, a
group of structurally similar compounds, show multiple hits:
oxibendazole (2.5-fold), mebendazole (2.42-fold), albenda-
zole (2.49-fold), and fenbendazole (2.15-fold). Interestingly,
each drug induced a greater degree of HRE activity than DFO
(1.89-fold at 10lM) (Fig. 1B).
Benzimidazoles stabilize HIF-1a
and induce HIF-regulated gene transcription
HIF-1a stability is primarily governed by HIF-PHDs,
which in the presence of oxygen hydroxylate HIF-1a within
its oxygen-dependent degradation domain (ODD). To es-
tablish whether albendazole and fenbendazole interfere with
HIF-PHD-regulated pathways, we tested these agents with a
reporter containing the HIF-1a ODD fused to luciferase (ODD-
Luc). The ODD-luc construct encoded in pcDNA3.1 plasmid
vector was constructed as previously described (47). Both al-
bendazole and fenbendazole increased ODD-Luc activity in a
concentration-dependent manner in HT22 cells (Fig. 2A), while
having no effect on a constitutive cytomegalovirus (CMV) lu-
ciferase construct (not shown). HRE activation customarily
results from stabilization of HIF-1a followed by binding of a
HIF-1a/HIF-1b heterodimer to the HRE. To establish whether
increased activity of HRE-Luc reporter by benzimidazoles re-
flects the stabilization of HIF-1a protein in HT22 cells, we
performed immunoblots using an antibody specific for HIF-1a.
As a positive control, we used a 100lM DFO, which was 10-
fold higher than our screening dose of benzimidazoles. For
validation purposes, we used albendazole and fenbendazole,
two agents commonly applied in clinical practice in humans and
animals. As shown in Figure 2B, they induce HIF-1a protein at
the screening dose (10lM) in HT22 cells.
These findings suggest that benzimidazoles are interdicting
an aspect of canonical oxygen-dependent signaling. To verify
these results in post-mitotic neurons, we treated primary mouse
cortical neurons with albendazole and fenbendazole, and found
that each induced mRNA levels of p21cip1/waf1 (p21), an es-
tablished HIF-1-regulated gene (Fig. 2C). As expected, alben-
dazole and fenbendazole also increased p21 protein levels (Fig.
2D). Together, these data suggest that benzimidazoles induce
HIF stability via a canonical HIF-PHD-regulated mechanism,
resulting in increased HIF-dependent gene expression.
Benzimidazoles do not regulate HIF activity through
inhibition of mitochondrial function
To understand how benzimidazoles might stabilize HIF,
we focused on their known activity in killing parasites. One
possibility is having global effects on mitochondrial function.
To investigate the global effects on mitochondrial function,
we measured mitochondrial membrane potential, oxygen
Table 1. Drugs That Activate HRE-Luc Reporter
Name Fold increase
Known HIF activators
Tilorone 9.76
Ciclopiroxolamine 2.99
Deferoxaminemesylate 1.89
Hydralazine 1.61
Antihelminthics
Oxibendazole 2.5
Albendazole 2.49
Mebendazole 2.42
Fenbendazole 2.15
NSAIDs
Indoprofen 4.18
Nabumetone 2.69
Zomepirac sodium 2.19
Ibuprofen 1.89
Antibiotics
Monesin sodium 2.41
Clofoctol 2.31
Trimethoprim 2.05
Clindamycin hydrochloride 1.99
Sulfachlorpyridazine 1.98
Nafcillin sodium 1.86
Anabolic isoflavones
Methoxyisoflavone
(7-methoxy-5-methyl-2-
phenyl-chromen-4-one)
2.37
Ipraflavone or ipriflavone 2.32
Biochanin A 2.19
Daidzein 2.11
Antihistamines
Hydroxyzine pamoate 2.36
Triprolidine hydrochloride 2.12
Tripelennamine citrate 2.09
Antineoplastics
Helenaline 2.03
Hydroxyurea 2.02
Semustine 1.94
Channel blockers and neuroreceptor modulators
Tropicamide 2.47
Pramoxine hydrochloride 2.46
Atenolol 2.43
Xylometazoline 2.18
Pirenzepine hydrochloride 2.15
Aminopyridine 2.08
Amiodarone hydrochloride 1.99
Mephenesin 1.97
Hyoscyamine 1.86
Clidinium bromide 1.80
Miscellaneous
Tryptophan 2.87
Anisindione 2.69
Carbetapentane citrate 2.42
Phenazopyridine hydrochloride 2.36
Colchicine 2.08
Clofibric acid 1.91
Piperin 1.84
Trioxsalen 1.8
HIF, hypoxia-inducible factor.
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consumption rate, and reactive oxygen species (ROS) pro-
duction in isolated mitochondria and found that these pa-
rameters were unchanged by exposure to benzimidazoles
(Fig. 3). A second mechanism is the inhibition of worm mi-
tochondrial enzymes, such as fumarase, that results in energy
depletion (33). In mitochondria, fumarase participates in the
tricarboxylic acid (TCA) cycle and is essential for oxidative
ATP synthesis. Inhibition of fumarase in worms can lead to
mitochondrial dysfunction, immobilization, and death of the
parasite (42). In humans, activity-inhibiting mutations of
fumarase lead to an accumulation of fumarate and succinate
in the cytoplasm and mitochondria. These metabolites are
proposed to promote HIF-1a stability by inhibiting HIF-
PHDs through competition with 2-oxoglutarate, a necessary
cofactor for prolyl hydroxylase activity (17, 48). To deter-
mine whether benzimidazoles stabilize HIF-1a by inhibiting
a TCA cycle enzyme, we measured the effect of benzimid-
azoles on fumarase activity. We found that of the four
benzimidazoles tested, only mebendazole inhibited fumarase
activity (Supplementary Fig. S1A; Supplementary Data are
available online at www.liebertpub.com/ars). However, this
occurs at concentrations that are 30-fold higher than those
used in our screen (10 lM) (Supplementary Fig. S1B). Si-
milarly, the enzyme activities of mitochondrial citrate syn-
thase and malonyl dehydrogenase were unchanged by these
benzimidazoles (data not shown). Based on these results, we
conclude that mitochondria are unlikely to be a direct target
for benzimidazoles in stabilizing HIF-1a in normoxia.
Benzimidazoles affect HIF stabilization/activity
through tubulin-binding activity
Another well-established and important target of antihel-
minthic benzimidazoles is tubulin (12, 25, 29). Antihelminthic
benzimidazoles bind to tubulin and prevent its polymerization
and subsequent formation of microtubules, although less ro-
bustly than classical microtubule depolymerizing agents (22)
(Supplementary Fig. S2). Since microtubules are important
FIG. 2. Secondary screens confirm activation of adaptive responses to hypoxia by benzimidazoles. (A) Quantification
of changes in an ODD-Luciferase activity, at 4 h after treatment with indicated doses of albendazole (Alb), fenbendazole
(Fen), and vehicle in HT22 cells stably transfected with ODD-Luc construct. DFO, 100lM was used as a positive control.
(B) Immunoblot analysis shows HIF-1a stabilization in HT22 cells at 4 h after treatment with DFO (100lM, as a positive
control), vehicle (Veh), albendazole (Alb), or fenbendazole (Fen). The band stabilized was verified to be HIF-1a using
siRNA-mediated knockdown (not shown). (C) Real-time polymerase chain reaction results show that mRNA levels of
p21cip1/waf1 (p21), an HIF-regulated gene, is upregulated by benzimidazoles in cultured embryonic cortical neurons at 8 h
after treatment with select benzimidazoles compared with vehicle. (D) Immunoblot of proteins from cultured cortical
neurons non-treated (Null), or treated with indicated doses of DFO (10lM) and benzimidazoles (1 lM) using a p21 antibody
shows an increased p21cip1/waf1 level at 20 h after treatment. Protein extract from p21cip1/waf1 null (p21- /- ) cortical neurons
was run as a negative control. Quantifications of results are presented as the mean of three independent experiments – SEM
(*p < 0.05, **p< 0.01, one-way ANOVA with Dunnett multiple-comparison test). ANOVA, analysis of variance; ODD,
oxygen-dependent degradation domain; SEM, standard error of mean.
124 ALEYASIN ET AL.
D
ow
nl
oa
de
d 
by
 L
eb
an
es
e 
A
m
er
ic
an
 U
ni
ve
rs
ity
 fr
om
 o
nl
in
e.
lie
be
rtp
ub
.c
om
 a
t 0
9/
05
/1
7.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
cytoskeletal components, they are essential for neuron struc-
ture, growth, and axonal trafficking. Drugs and mutations that
disrupt the dynamic equilibrium between free and polymer-
ized tubulin may alter neuronal physiology, including cell-
signaling pathways (7). In re-examining our hits (Table 1), we
noted that colchicine, a prototypical tubulin-binding drug,
also induced HRE-Luc activity to levels similar to benz-
imidazoles. To assess whether tubulin binding could be the
on-target effect of benzimidazoles and colchicine in increas-
ing HRE-Luc activity, we examined isocolchicine, a semi-
synthetic structural isomer of colchicine with transposed
C-ring carbonyl and methoxy groups. This structural modifi-
cation decreases isocolchicine affinity for tubulin by 500-fold
(16). Thus, if tubulin binding is an on-target effect, iso-
colchicine should not affect HRE-Luc activity at concentra-
tions equimolar to colchicine. Indeed, while colchicine
activated HRE-Luc in HT22 cells starting at 0.6lM, iso-
colchicine had no effect (Fig. 4A). Based on this model, we
predicted that other compounds which target the colchicine-
binding site of tubulin would also induce reporter activity.
Two such compounds, podophyllotoxin and nocodazole, were
found to significantly increase HRE-Luc activity. Of note, we
found that vinblastine, which depolymerizes microtubules by
binding to a distinct site on b-tubulin, also activated the re-
porter in a dose-dependent manner. In contrast, Taxol, which
stabilizes microtubules by binding to polymerized tubulin,
had no effect (Fig. 4B). Consistent with these observations,
colchicine, but not isocolchicine, increases ODD-Luc activity
(Fig. 4C). This suggests that HIF-activation after treatment
with tubulin-binding agents is through HIF-1a stabilization,
FIG. 3. Benzimidazoles have no effect on the respiration rates, the membrane potential changes, and ROS pro-
duction of isolated mitochondria. (A) The respiration rates of mouse liver mitochondria. The incubation buffer and other
conditions were as described in the Materials and Methods section. The compounds were added at 50lM each before mito-
chondria. The non-phosphorylating respiration (State 4) was recorded for 2–3 min, and the phosphorylating respiration (State 3)
was initiated by adding 400 nmol of ADP to the mitochondria suspension. (B) The membrane potential changes of mitochondria.
The amplitude of the membrane potential remaining after adding the compounds, ADP, or carboxyatractylate is presented in
percent of the total, taking the value of the membrane potential before adding the compounds as 100% and the value after
antimycin addition as 0% (fully de-energized mitochondria). (C) ROS emission in response to benzimidazoles. The data are
presented as average values of three experiments with standard errors. The data within the groups are not statistically different. (D)
An example of the membrane potential test. The membrane potential was measured as described in the Materials and Methods
section. Downward deflection of the curves means an increase in the membrane potential (DJ). The compounds were added at
50lM each where indicated. Other additions: ADP, 200 nmol ADP; carboxyatractylate (an inhibitor of ATP/ADP translocase)
was added at 1lM; antimycin (an inhibitor of Complex III of the respiratory chain) was added at 1lg/ml. (E) An example of the
ROS emission test. The ROS emission was measured as described in the Materials and Methods section. Upward deflection of the
curves means an increase in the H2O2 in the incubation medium. The compounds were added at 50lM each where indicated.
Other additions: antimycin (an inhibitor of Complex III of the respiratory chain) was added at 1lg/ml; rotenone (an inhibitor of
Complex I of the respiratory chain) was added at 1lM. The data are presented as average values of three to four experiments with
standard errors of mean (–SEM). The differences within the groups are not statistically significant. ROS, reactive oxygen species.
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likely via the inhibition of prolyl hydroxylation. Taken to-
gether, these observations suggest that benzimidazoles, sim-
ilar to other agents which bind monomeric tubulin, induce
HIF-dependent gene expression under normoxia by stabiliz-
ing HIF-1a through an ODD-dependent mechanism.
Benzimidazoles and other agents that bind
to tubulin protect embryonic cortical neurons
against oxidative stress
To examine whether activation of the hypoxic adaptive re-
sponse by benzimidazoles is associated with neuroprotection,
we tested them in a glutathione depletion model of oxidative
stress in immature primary neurons using the glutamate analog,
homocysteic acid (HCA). Extracellular HCA inhibits cystine
uptake by the system Xc- antiporter, and depletes intracellular
glutathione by reducing its precursor, cysteine. This leads to the
disruption of the oxidant-antioxidant balance in favor of oxi-
dants and, ultimately, leads to cell death. Our lab and others
have used this model to identify a number of novel pathways
and drugs, including inhibitors of the HIF-PHDs, that have
shown neuroprotection in preclinical models of acute and
chronic neurodegeneration (3, 26, 30, 44, 52). We found that
the tubulin-binding drugs colchicine and nocodozole protected
neurons from HCA-induced oxidative stress (Fig. 5A, B, and
D), while isocolchicine had no effect at the same concentrations
(Fig 5C, D). Each benzimidazole identified in our screen pro-
tected neurons against oxidative stress in a dose-dependent
manner (Fig. 6A–E). However, higher concentrations of
benzimidazoles (‡ 1lM for oxibendazole and ‡ 2lM for
others) show a gradual negative impact on the basal viability.
We also observed that while colchicine protects the soma
during oxidative stress, it disrupts the neurites (Fig. 5D).
To examine the effects of benzimidazoles on microtubule-
dependent neuronal structures such as axons and dendrites, we
stained embryonic cortical neurons after treatment with benz-
imidazoles with an antibody that recognizes a neuron-specific
tubulin, bIII tubulin. Treatment with fenbendazole within the
neuroprotective dose did not change the morphology of neu-
rons (Fig. 7). Together, our data support a model in which
tubulin-binding drugs, including benzimidazoles, activate
hypoxic adaptation and show neuroprotective activity against
oxidative stress without gross changes in neuronal morphology.
Pretreatment with Taxol inhibits neuroprotective
activity of tubulin-binding agents
If binding to free tubulin by benzimidazoles is necessary
for the initiation of the signaling cascade that activates hyp-
oxic adaptation and neuroprotection from oxidative stress,
FIG. 4. Activation of markers of hypoxic adaptive re-
sponse by tubulin-binding agents. (A) HT22 cells stably
expressing HRE-Luc were treated with indicated concentrations
of colchicine and isocolchicine. Isocolchicine is a structural
isomer of colchicine that binds to tubulin with a much lower
affinity. Colchicine increases HRE-luciferase activity, while
isocolchicine does not (the difference of luciferase activity in
Iso and vehicle-treated cells is not statistically significant at any
dose). (B) Similar to colchicine, other tubulin-binding agents,
including podophyllotoxin (PPT), vinblastine (Vin), and noco-
dazole (Noc), increase HRE-Luc expression; while taxol (Tax,
which binds to and promotes microtubular stabilization) does
not. The difference of luciferase activity in taxol and vehicle-
treated cells is not statistically significant at any dose. (C)
Colchicine increases the stability of the ODD-Luc reporter in
HT22 cells at the dose of 1lM, while isocolchicine has no
effect at 1 or 10lM. One hundred micromolar of DFO was
used as a positive control. These findings suggest that tubulin-
binding agents which classically destabilize microtubules and
release free tubulin stabilize HIF and activate HIF-dependent
gene expression similar to benzimidazoles. Quantifications of
results are presented as the mean of three independent ex-
periments–SEM (*p< 0.05, **p< 0.01, and ***p< 0.001 [or
each of corresponding symbols], one-way ANOVA with
Dunnett multiple-comparison test).
‰
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then reduction of free tubulin should abrogate the protective
actions of these drugs. To test the hypothesis, we first verified
that Taxol reduces free tubulin levels in cortical neurons (Fig.
8A, B). We then pretreated primary neurons with 0.1 lM
Taxol, 30 min before treatment with the tubulin-binding
agents. This dose of Taxol does not cause significant neuro-
toxicity in cortical neurons (Fig. 8C). We used doses of
tubulin-binding agents previously shown to provide maxi-
mum neuroprotection (Figs. 5 and 6). Taxol promotes mi-
crotubule stability, driving tubulin monomer into polymer
(Fig. 8A); pretreatment with Taxol completely abrogated the
neuroprotection conferred by tubulin-binding compounds,
including benzimidazoles (Fig. 8C). To verify that reversal of
protection was due to a specific effect of Taxol, we examined
the effect of Taxol pretreatment on neuroprotection from
HCA by an agent not known to bind tubulin, N-acetylcysteine
(NAC). We have previously shown that NAC prevents glu-
tathione depletion-induced death by enhancing intracellular
glutathione levels (43). As expected, Taxol did not change
the neuroprotective effect of NAC, suggesting that Taxol’s
ability to reverse protection is specific to that induced by
drugs which bind to tubulin monomer. Moreover, the ability
of Taxol to nullify both protective effects of classical tubulin
binders and benzimidazoles is consistent with these agents
working via a similar mechanism.
Mebendazole inhibits degradation of ODD-Luc,
a surrogate marker of HIF activation, in vivo
Our findings suggested that benzimidazoles activate hyp-
oxic adaptation and reduce oxidative death in vitro. However,
one of the many challenges in translating the results of cell-
based and invertebrate assays to more clinically relevant
models in mammals is the unpredictable bioavailability of
these compounds. Indeed, clear demonstration that the con-
centration of drug delivered safely to an animal affects a
biomarker of drug activity studied in in vitro systems is es-
sential. For example, benzimidazoles such as mebendazole
are taken orally in clinical settings. The question remained as
to whether oral mebendazole reaches sufficient concentra-
tions to stabilize HIF-1a there. To evaluate HIF stabilization
in the brain after treatment with these drugs, we used a
transgenic mouse strain that ubiquitously expresses the HIF
reporter ODD-Luc (47). We administered albendazole and
mebendazole via oral gavage, daily for 5 days. After 6 h of the
last dose, mice were anesthetized and then underwent live
bioluminescence imaging using an IVIS-100 system. We
observed that mebendazole, at a dose of 50 mg/kg, increased
ODD-Luc activity fourfold in the brain compared with the
control group (Fig. 9). By contrast to mebendazole (5),
albendazole showed only a weak signal increase in the liver
FIG. 5. Tubulin binding agents provide neuroprotection against oxidative stress. (A, B) Tubulin-binding agents
colchicine (Col) and nocodazole (Noc) protect embryonic cortical neurons against oxidative stress induced by the glutamate
analog, HCA. Glutamate or HCA inhibit cystine uptake, leading to depletion of the antioxidant, glutathione. (C) Iso-
colchicine (Iso) does not protect cortical neurons against oxidative stress at any of the tested concentrations. Survival for
(A–C) was quantified by spectrophotometric assessment of the quantity of MTT converted to blue formazan. (D) Live-dead
assay shows the micrograph of cultured neurons after treatment with 0.5 lM colchicine and isocolchicine with or without
HCA. Quantifications of results are presented as the mean of three independent experiments – SEM (*p < 0.05, **p < 0.01,
and ***p < 0.001, one-way ANOVA with Dunnett multiple-comparison test). HCA, homocysteic acid.
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with no detectable effect in the brain at a dose of 150 mg/kg
(data not shown).
Discussion
Antihelminthic benzimidazoles are used throughout the
world to treat parasitic infestations in a host of species and in
diverse organs, including the central nervous system (CNS).
An on-target effect of these agents is b-tubulin; specific mu-
tations in this gene can confer resistance to antihelminthics
(24). The study of the interaction of antihelminthic benz-
imidazoles with mammalian tubulin and its biological effect
on the host, previously underappreciated, has developed into
an area of growing interest. Indeed, two groups described the
ability of benzimidazoles to modulate expression of PGC-1a,
a co-activator involved in mitochondrial biogenesis, and to
decrease ROS formation in non-neural cells (4, 58). Here, we
expand our understanding of the host effects of benzimid-
azoles in neurons and show that these agents stabilize HIF-1a
and augment HIF-dependent transcription. We correlate these
changes with the ability of benzimidazoles to confer resis-
tance to oxidative death in primary cortical neurons. Three
lines of evidence suggest that free b-tubulin is targeted to
achieve these biological effects. First, the effects of benz-
imidazoles on HIF-dependent gene expression and neuro-
protection can be mimicked by structurally diverse agents that
bind tubulin monomer, including those which interact with
colchicine- or vinca alkaloid-binding sites. Second, the effects
of colchicine on hypoxic adaptation and neuroprotection are
abrogated by chemically modifying it to isocolchicine, which
possesses a 500-fold lower affinity for tubulin than the parent
compound. Third, reducing free tubulin levels with Taxol
counteracts the protective effects of benzimidazoles.
Several models could explain the ability of drugs that bind b-
tubulin to mimic hypoxia and prevent death in neurons. It is
possible that these agents act to shift microtubule-tubulin equi-
librium in favor of depolymerization, although we do not ob-
serve a gross change in neuronal architecture assessed by bIII
FIG. 6. Benzimidazoles protect
cultured cortical neurons against
oxidative stress. (A–D) All four
clinically approved benzimidazoles
protect embryonic cortical neurons
from HCA-induced death. Neuronal
survival was assessed by MTT assay.
(E) Live-dead assay shows the mi-
crograph of cultured neurons after
treatment with 0.5lM of benzimid-
azoles with or without HCA. Quan-
tification of results is presented as the
mean of three independent experi-
ments–SEM (*p<0.05, **p<0.01,
and ***p<0.001, one-way ANOVA
with Dunnett-multiple comparison
test).
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tubulin staining in benzimidazole-treated neurons (Fig. 7). Small
changes in microtubule dynamics are known to modulate sig-
naling events that can lead to de novo transcription. For example,
the cytoplasmic inhibitor of the transcription factor NF-jB, IjB
can be sequestered by microtubules in the axonal initial segment.
On microtubule depolymerization, IjB is degraded, unmasking
the nuclear localization sequence of NF-jB and allowing it to
translocate to the nucleus where it can up-regulate a number of
genes, including HIF-1a (19). Increases in HIF-1a transcription
could overwhelm the ability of neurons to degrade HIF-1a and
lead to its stabilization. In this scheme, HIF-1a induction may be
a biomarker of other genes that are known to abrogate oxidative
stress, such as MnSOD (9), rather than being responsible for
protection itself (49). Of course, it is also possible that benz-
imidazoles act post-transcriptionally rather than transcription-
ally to enhance the interaction of HIF-1a (and other proteins)
with Septins, a group of microtubule polymerizing guanine nu-
cleotide-binding proteins which lead to HIF-1a stabilization in
tumors (2). Since some of the earlier reports indicate that uptake
and intracellular trafficking of iron and iron transporting proteins
such as transferrin receptor and metal transporter protein 1
(MTP1) is microtubule dependent (34, 60), it is possible that
benzimidazoles, through their tubulin-binding activity, might
interrupt the intracellular trafficking of iron, an important co-
factor for the activity of prolyl hydroxylases. Cytosolic iron
starvation could lead to loss of HIF-PHD activity, stabilization of
HIF, activation of HIF target genes, and HIF-independent neu-
roprotection (49, 50, 61).
FIG. 7. Neuroprotective concentrations of antihelminthic
benzimidazoles show no gross disruption of cortical neuron
morphology. Immunocytochemical staining of embryonic
cortical neurons at 16 h after treatment with 1lM of fenben-
dazole using b-tubulin III antibody compared with colchicine
(1lM) and isocolchicine (1lM) as positive and negative
controls (scale bar=25lm, insets represent digitally magnified
indicated area by 2· ). To see this illustration in color, the
reader is referred to the web version of this article at
www.liebertpub.com/ars
FIG. 8. Pretreatment with taxol abrogates the neuro-
protective effects of tubulin-binding agents. (A) After 3 h
of treatment with indicated concentrations of colchicine and
taxol (Tax) in cultured embryonic neurons, free and poly-
merized tubulin, respectively, were monitored in the soluble
(S) and insoluble (pellet, P) fractions, by immunoblotting
with a b-tubulin-specific antibody. (B) Quantification of
densitometry data from the three Western blot analyses
shows that taxol significantly reduced the levels of free tu-
bulin at both 1 and 0.1 lM doses. Since cortical neurons
could tolerate 0.1 lM of taxol without significant toxicity
(data not shown), we used this concentration for the pre-
treatment experiment. (C) As shown earlier, treatment with
tubulin-binding agents, colchicine (0.03 lM), nocodazole
(0.06lM), and antihelminthic benzimidazoles (1 lM) pro-
tects neurons against glutathione depletion-induced death.
Pretreatment with taxol (0.1lM) for 30 min nullifies the
neuroprotective effects of the tubulin-binding agents. The
difference in the survival rate between vehicle and taxol-
treated groups without HCA was statistically not significant.
Quantifications of results are presented as the mean of three
independent experiments–SEM (*p< 0.05, and ***p< 0.001,
one-way ANOVA with Dunnett multiple-comparison test).
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The antihelminthic benzimidazoles are the first line treat-
ment for parasitic infestations and are believed to be vermi-
cidal by disrupting worm microtubules, leading to parasite
immobility and death (57) without similarly affecting host
cells. An unexplored possibility consistent with the results
presented here is that host cells, unlike parasites, augment
genetic adaptation in response to benzimidazole exposure
that prevents extensive microtubular disruption. Indeed, a
recent study shows that cytoskeletal insult through depoly-
merization of synaptic microtubules can lead to reduction of
FOXO via activation of Akt to help limit microtubule dis-
ruption (39). Irrespective of the mechanism for selective
toxicity in parasitic helminths by benzimidazoles, our find-
ings show that they protect neurons in the nanomolar range.
Finally, using a well-validated reporter, we demonstrate that
mebendazole stabilized HIF-1a in the brain, a biomarker of
hypoxic adaption. In clinics, the drug of choice to treat
neurocysticercosis is albendazole. The concentration of its
main metabolite, albendazole sulfoxide achieves levels in the
brain that are sufficient to eradicate parasites (20). However,
our finding that (i) albendazole sulfoxide is a weak neuro-
protective agent compared with the parent compound (Sup-
plementary Fig. S3), and (ii) albendazole failed to activate the
HIF pathway in the brain, makes albendazole a less favorable
therapeutic candidate than mebendazole in evaluating the
effects of these agents on neurological conditions.
In addition to the novel potential applications for anti-
helminthic benzimidazoles, our studies also introduce numer-
ous compounds with current clinical approval and short- and
long-term safety data in humans that have the unexpected
ability to activate hypoxic adaptation. A closer look at the list
of our hits reveals at least two other groups of pharmaco-
phores, isoflavones and phenylpropionic acids (ibuprofen
and indoprofen). Of note, zomepirac, a non-steroidal anti-
inflammatory drug, also a hit in our screen, binds to tubulin
and mildly inhibits microtubular assembly (6). While the
results of our primary screen have yet to be fully vetted, drugs
such as hydralazine, atenolol, aminopyridine, and hydroxy-
zine with known applications in stroke prevention (11),
functional recovery (10), or as CNS antihistamines (13) are of
particular interest as novel activators of the adaptive program
to hypoxia.
Materials and Methods
Chemicals
Albendazole, mebendazole, fenbendazole, oxibendazole,
colchicine, nocodazole, citrate synthase and malic dehydro-
genase, fumarase, oxaloacetic acid, acetyl-CoA, b-NADH, b-
NAD, l-malic acid, fumaric acid, and DFO were purchased
from Sigma and used without further purification.
Cell culture
Cortical neurons were harvested from E.15 CD-1 mouse
embryos as previously described for rat cortical cultures (36).
Dissociated neurons were plated in minimum essential media
supplemented with glutamax, 10% fetal bovine serum (FBS),
and 5% horse serum and seeded in 96-well (9 · 104 cells/
well) or 6-well plates (2 · 106 cells/well), or 10 cm dishes
(1 · 107 cells/dish) that were precoated with poly d-lysine.
HT22 mouse hippocampal neuroblasts were cultured in
Dulbecco’s modified Eagle medium (Invitrogen) with high
glucose, supplemented with glutamine, FBS (10%), and
penicillin/streptomycin (Invitrogen).
ODD-luciferase activity
The ODD-luc construct encoded in pcDNA3.1 plasmid
vector was constructed as previously described (47). Hy-
droxylation of prolines P402 and P564 within the HIF-1a
ODD by HIF-PHDs permits binding to the VHL protein that
targets it for proteasomal degradation. Targeted P402A and
P564A mutation within the ODD prevents hydroxylation and
confers stability to HIF-1a or the ODD-Luc construct under
normoxia. ODD-Luc activity can, therefore, be used as a
surrogate for HIF-1a stability regulated by the HIF-PHDs
(47, 53). To make stably expressing ODD-Luc hippocampal
mouse neuroblast HT22 cells, we co-transfected the plasmid
construct along with a puromycin resistance plasmid (p-
BABEpuro). Transfected cells were grown in the presence of
FIG. 9. Activation of the host hypoxic
adaptive response in vivo after treatment
with mebendazole. Mebendazole or vehicle
was delivered to ODD-Luc mice through
oral gavage at 50 mg/kg for 5 days. Six
hours after the last dose, the animals were
subjected to bioluminescence imaging using
the IVIS 100 system (A). The relative in-
tensity of the luciferase activity of the ROI
in head (marked as the red circle) was
compared between vehicle (n = 5) and me-
bendazole-treated (n = 8) mice (B). Quanti-
fications of results are presented as the
mean – SEM (*p < 0.05, Student’s t-test).
ROI, region of interest.
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4 lg/ml of puromycin. Luciferase activity was measured by
luciferase assay kit (Promega) using an LMaxII microplate
luminometer (Molecular Devices). ODD-Luciferase activity
was normalized to the protein content of each well measured
by bicinchoninic acid (BCA) protein assay (Pierce).
Neuronal viability assay
After 1 day in culture in 96-well plates, neurons were co-
treated with an indicated concentration of each drug and
homocysteic acid (HCA, 5 mM) to induce neuronal death via
glutathione depletion (43). The compounds were solubilized in
dimethyl sulfoxide (DMSO). To keep benzimidazoles soluble
during serial dilution, we used 50% ethanol. The final con-
centration of ethanol in the culture media was 0.1%. For mi-
crotubule prestabilization experiments, the neurons were
exposed to 100 nM of Taxol for 30 min before co-treatment with
the compounds and HCA. Viability was assessed at 16 h after
treatment by the MTT assay, or calcein AM/ethidium homo-
dimer-1 staining (live-dead assay) (Invitrogen) under fluores-
cence microscopy according to the manufacturer’s protocol.
The viability has been calculated as the ratio of MTT absor-
bance in three treated wells divided by the average of three
untreated wells in each plate and presented as percent to control.
Western blot analysis
Cells were plated in 10 cm plates, treated with the indi-
cated compounds overnight, and then lysed with NP-40
buffer supplemented with protease inhibitors. For HIF-1a
blots, nuclear proteins were enriched using a nuclear/cyto-
plasmic subcellular fractionation kit (Pierce). Protein content
was measured by BCA protein assay (Pierce). Thirty mi-
crogram of total protein for p21cip1/waf1 (p21) and 100 lg of
nuclear protein for HIF-1a were loaded on 10% or 4%–12%
gradient Bis-Tris polyacrylamide gels respectively (Invitro-
gen), resolved, and transferred to nitrocellulose membranes.
Membranes were probed by antibodies against p21 (1:200;
Santa Cruz), b-tubulin III (1:10,000; Epitomics), HIF-1a
(1:500; Novus Biologicals), or histone H3 (1:1000; Cell
Signaling Technology) and developed by IR-dye-conjugated
antibodies (1:15,000) using the LI-COR system. Blots were
imaged with the Odyssey IR quantitative Western blot de-
tection system (LI-COR Biosciences).
Immunocytochemistry
Cortical neurons were treated with indicated compounds,
fixed with 4% paraformaldehyde, and incubated with anti-b-
tubulin III antibody (1:200; Epitomics), followed by sec-
ondary antibody as previously described (15).
Isolation of mitochondria
Non-synaptic mouse brain mitochondria were isolated by a
modified isopycnic centrifugation procedure employing
Percoll density gradient (32, 51). Briefly, cortex brain tissue
was homogenized in the MSEGTA buffer composed of
225 mM mannitol, 75 mM sucrose, 20 mM HEPES (pH 7.4),
1 mM EGTA, and 0.2% (w/v) fatty acid-free bovine serum
albumin (BSA) and centrifuged at 2000 g · 4 min. The su-
pernatant was collected and centrifuged at 12,000 g · 10 min.
The pellet was re-suspended in MSEGTA, layered over 25%
(v/v) Percoll prepared in MSEGTA mixture, and centrifuged
at 30,000 g · 10 min. Purified mitochondria fraction was
collected at the bottom of the tube, re-suspended in MSEGTA
without added BSA, and washed twice by centrifugation at
12,000 g· 10 min. Final mitochondrial pellet was re-
suspended in MS buffer comprising 225 mM mannitol,
75 mM sucrose, and 20 mM HEPES (pH 7.4) and stored on
ice. Protein content was estimated by a commercial BCA
assay (Pierce Biotechnology/Thermo Scientific).
Mouse liver mitochondria were isolated by differential
centrifugation. Liver was homogenized in MSEGTA buffer
and centrifuged at 900 g · 10 min; the supernatant was col-
lected and centrifuged at 10,000 g · 10 min; and the pellet
was re-suspended in MSEGTA buffer with BSA omitted and
centrifuged at 10,000 g · 10 min. The final pellet was re-
suspended in MSEGTA buffer without BSA to 15–20 mg
mitochondria protein per milliliter and stored on ice during
the experiment.
Functional assays
The base KEGTA incubation buffer employed in all assays
was composed of 125 mM KCl, 20 mM HEPES (pH 7.2),
0.2 mg/ml BSA (fatty acid free), 4 mM KH2PO4, 0.2 mM
EGTA, 5 mM glutamate, and 2 mM malate. For the mea-
surements of the mitochondrial membrane potential, KEGTA
was supplemented 2 · 10- 6 M Safranine O. Mitochondria at
0.1–0.12 mg/ml were added to 1 ml of incubation buffer in a
stirred thermostated (t= 37C) cuvette, and the changes in the
membrane potential were recorded by following the fluo-
rescence of Safranine O with excitation and emission
wavelengths of 495 and 586 nm, respectively, using a Hitachi
4500 (‘‘Hitachi’’) spectro-fluorimeter as described earlier
(54, 55). For the measurements of mitochondrial ROS
emission, KEGTA was supplemented with 4 U/ml of horse-
radish peroxidase, 40 U/ml of Cu, Zn superoxide dismutase,
and 1 · 10 - 5 M Amplex RedUltra (Invitrogen). A change in
the concentration of H2O2 in the medium was detected by
fluorescence of the oxidized Amplex RedUltra product using
excitation and emission wavelengths of 555 and 581 nm,
respectively (54, 55). The response of Amplex RedUltra to
H2O2 was calibrated by sequential additions of known
amounts of H2O2. The concentration of commercial 30%
H2O2 solution was calculated from light absorbance at
240 nM employing E240 = 43.6 M- 1 · cm - 1; the stock solu-
tion was diluted to 0.1 mMwith water and used for calibration
immediately. The rates of resting and phosphorylating res-
piration were recorded with Oxytherm oximeter (Hansatech),
at 37C and 0.5–0.7 mg/ml of mouse liver mitochondria. All
compounds were dissolved in DMSO at 25–50 mM.
Fumarase assay
Fumarate production from malate was measured with
continuous monitoring of optical density at 240 nm, corre-
sponding to the maximum absorption of fumarate (E= 2440
M- 1 · cm - 1) in 0.1 M K-phosphate buffer, pH 7.6, in the
presence of varied concentrations of benzimidazole and
malate (0.05–0.4 mM). The data were plotted in a double-
reciprocal format to compare inhibitory effects of various
benzimidazoles, and on Dixon coordinates to determine the
inhibition constant (Ki).
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RNA extraction and real-time polymerase chain
reaction
Cortical neurons were cultured in six-well plates and
treated with indicated drugs. After 8 h, neurons were har-
vested with Trizol (Invitrogen). The levels of p21cip1/waf1
(cdkn1a) mRNA were analyzed using One-step Taqman PCR
assay mix and primers (Mm00432448_m1) on a 7500 Fast
Real-Time PCR system (Applied Biosystems). b-Actin was
used as an endogenous control (Mm00607939_s1).
Tubulin polymerization assay
The levels of free and polymerized tubulin were assessed
at 3 h after treatment with indicated microtubule-binding
agents using a microtubule/tubulin in vivo assay kit (Cyto-
skeleton).
Mebendazole treatment and in vivo bioluminescence
imaging
Adult FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/
J ODD Luc transgenic mice purchased from Jackson La-
boratories were used to evaluate the inhibition of HIF-PHDs
in vivo. For drug treatments, mebendazole tablets were
powdered, mixed in a vehicle that was composed of phos-
phate-buffered saline and sesame oil 1:1 (Sigma), and de-
livered via oral gavage (100 ll) to adult ODD Luc mice.
Animals were treated with mebendazole (50 mg/kg) or ve-
hicle once a day for 5 days. Six hours after the last treatment,
animals received an intraperitoneal injection of firefly D-
luciferin potassium salt (75 mg/kg; i.p.) and were anesthe-
tized with a mixture of 2.5% isoflurane and oxygen. The mice
were placed in the chamber, where anesthesia was main-
tained with isoflurane 2%, administered through a nosecone
via a gas anesthesia system. Luciferase luminescence was
evaluated by a 100 Series IVIS Imaging System (Caliper Life
Sciences, PerkinElmer). Mice were imaged on the dorsal side
at 10 min post D-luciferin injection. The bioluminescent
signal was integrated every 10 min for 40 min, with the peak
signal observed at 20 min in most of the animals. Integral
luminescence from a defined region of interest around each
animal’s brain was measured using the Living Image Soft-
ware and expressed as photons per second of light.
Statistical analysis
Data were analyzed using Prism (GraphPad software).
Quantitative data are presented as mean – standard error of
mean of at least three experiments. A comparison between
the groups and control was performed by one-way analysis of
variance (ANOVA), followed by post hoc Dunnett multiple-
comparison test or Student’s t-test for two-group analysis.
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